There is good news for the more than 40,000 men per year who go to the hospital for diagnosis because of elevated Prostate-Specific Antigen (PSA) levels. With a negative MRI diagnosis, ultrasound-guided prostate biopsies will no longer be required. This is the result of the 4M study, which is published today in European Urology. “Thanks to the use of MRI, we can reduce the number of prostate biopsies by half,” says Jelle Barentsz, Professor of Radiology, who led the study. The new guidelines for diagnosis of prostate cancer, to be published in early 2019, will include the use of MRI.The current guidelines for the diagnosis of prostate cancer prescribe ultrasound-guided prostate biopsies to determine whether cancer is present in patients with elevated PSA levels. In this process, pieces of tissue are removed from twelve locations in the prostate. However, prostate tissue can be evaluated more accurately with an MRI scan. Consequently, patients with a negative diagnosis for prostate cancer based on the MRI scan do not have to undergo a prostate biopsy. In 2017, Radboudumc therefore replaced the ultrasound-guided prostate biopsy with an MRI scan to diagnose men with elevated PSA levels.
To test the use of MRI in prostate diagnostics nationwide, the 4M study (Met prostaat-MRI Meer Mans) was performed between 2015 and 2017 under the supervision of PhD candidate Marloes van der Leest. This study was funded by Alpe d’Huzes. At three centers in the Netherlands, the MRI diagnostic method was compared with the ultrasound method in 626 men with elevated PSA levels. All men first underwent an MRI scan to evaluate whether cancer was actually present. This scan showed that approximately half of them had indications of high-risk cancer. These men then underwent a MRI-guided prostate biopsy, in which two to four pieces of tissue were taken.
Less unnecessary treatment
To compare the results of the MRI diagnosis with the standard practice of ultrasound-guided biopsy, all participants underwent both methods. With MRI diagnosis, fewer low-risk forms of cancer were mistaken for high-risk cancer. This means that the MRI method can largely prevent over-diagnosis and unnecessary treatment of prostate cancer.
Twelve-needle biopsy no longer required for most patients
The results of the study showed that the MRI method is just as reliable as the standard – but more invasive – ultrasound-guided method. And that is good news for patients, says Professor of Radiology Jelle Barentsz: “With this method, approximately 20,000 men per year can avoid the 12-needle prostate biopsy. Patients with elevated PSA levels who do not present with a high-risk form of cancer on the first MRI scan do not have to undergo a biopsy, but must continue to monitor their PSA levels.”
An ultrasound-guided prostate biopsy will follow only if a doctor strongly suspects high-risk prostate cancer despite a negative result from the MRI method.
In the Netherlands, patients with elevated PSA levels and a suspicion of prostate cancer are referred by their GP to one of the specialized prostate diagnosis centers in the Netherlands. “At these centers, doctors specialize in performing MRI prostate scans. As a result, prostate biopsies can be avoided in 49% of the patients. However, for patients who are referred to non-specialist centers, this figure drops to 28%,” explains Barentsz. The recommendations from the 4M study are being included in the preparation of the new guidelines for prostate diagnostics, which are expected to be published in early 2019.
See also: https://www.radboudumc.nl/nieuws/2017/binnen-twee-weken-diagnose-prostaatkanker
Read more about the diagnosis of prostate cancer in our dossier on the website: https://www.radboudumc.nl/nieuws-en-media/dossiers/uitgelichte-onderwerpen/prostaatkanker
Jelle Barentsz is member of theme Urological cancers.
Related news items
Radboudumc research most lungs recover well after COVID-1926 November 2020
In severe COVID-19 patients the lung tissue recovers well in most cases. This is shown in research by the Radboudumc, published in Clinical Infectious Diseases. Striking conclusion: patients who were referred by the general practitioner recover worse than ICU patients.read more
Marianne Boenink has been appointed professor in Ethics of Healthcare26 November 2020
Health scientist and philosopher Marianne Boenink has been appointed professor in Ethics of Healthcare at the Radboud University/ Radboudumc, as of 1 August 2020.read more
The effects of the COVID-19 pandemic on (future) parents and their babies26 November 2020
While the corona crisis affects all of us, people who have just started a family or are trying to, are doing this in a sub-optimal situation. Researchers are trying to find out how the ongoing crisis is affecting them.read more
Patrick Jeurissen member Scientific Advisory Board for European Commission on health care policy in pandemics26 November 2020
Patrick Jeurissen, Professor of Affordability of Care, has been appointed as a member of the Scientific Advisory Board for the Pan-European Commission on Health and Sustainable Development. This committee will study healthcare policy in the light of pandemics in the coming year.read more
Erik van der Heijden received The Distinguished WABIP Regent Award26 November 2020
The 21st World Conference on Bronchoscopy and Intervention Pulmonology (WCBIP) is currently taking place in Shanghai. This is organized by the WABIP. Erik van der Heijden, member of the scientific organizing committee, received the prize ‘The Distinguished WABIP Regent Award'.read more